Pros | ![]() Among most bought funds within the category. ![]() Larger AUM within category. ![]() Beats FD returns for both 3Y & 5Y duration. | ![]() 5Y returns in the top 25% of the category. ![]() 3Y returns in the top 25% of the category. ![]() Among most bought funds within the category. | ||
Cons | - | - |
INDMoney rank | 7/8 | 4/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 12 Years | 6 Years | ||
Fund Size | 8081 Cr | 3019 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹100 | ||
Expense Ratio | 0.91% | 0.63% | ||
Exit Load | 1% | 0.5% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 40 | 33 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (13.43%) Divi's Laboratories Ltd (9.28%) Lupin Ltd (7.27%) Cipla Ltd (5.71%) Apollo Hospitals Enterprise Ltd (5.31%) | Sun Pharmaceuticals Industries Ltd (10.78%) Suven Pharmaceuticals Ltd (9.49%) Cipla Ltd (8.55%) Ipca Laboratories Ltd (7.98%) Globus Medical Inc Class A (5.58%) | ||
No of Sectors | 1 | 2 | ||
Top 3 Sectors | Health (100%) | Health (98.55%) Financial Services (1.45%) | ||
Equity % | 99.46% | 99.18% | ||
Debt % | - | - | ||
P/E | 35.57 | 38.2 | ||
P/B | 5.87 | 4.87 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 4.1% | 2.33% | ||
3-Month Return | -2.83% | -8.21% | ||
6-Month Return | -8.27% | -10.21% | ||
1-Year Return | 15.16% | 16.5% | ||
3-Year Return | 18.88% | 20.17% | ||
5-Year Return | 23.8% | 26.51% |
Sharpe | 0.81 | 0.9 | ||
Alpha | 0.5 | 2.42 | ||
Beta | 0.9 | 0.87 | ||
Standard Deviation | 15.85 | 15.95 | ||
Information Ratio | -0.21 | 0.16 |
Description | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | DSP Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Sailesh Raj Bhan,Kinjal Desai | Chirag Dagli |